Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer's disease

Neurology

Volumn 60, Issue 2, 2003, Pages 246-252

  Bennett, D A ^a,b,c   Wilson, R S ^a,b   Schneider, J A ^a,b   Evans, D A ^a,b   Aggarwal, N T ^a,b   Arnold, S E ^d   Cochran, E J ^b   Berry Kravis, E ^b   Bienias, J L ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

AGED; ALLELISM; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL FEATURE; COGNITION; CORRELATION ANALYSIS; DEPTH PERCEPTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEMORY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENILE PLAQUE; AGE; ALLELE; BRAIN; COGNITIVE DEFECT; DISEASE COURSE; EDUCATIONAL STATUS; GENETIC PREDISPOSITION; GENETICS; LONGITUDINAL STUDY; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; RISK; RISK FACTOR; STATISTICAL MODEL; STATISTICS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; EDUCATIONAL STATUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; RISK FACTORS;

EID: 0037469076     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000042478.08543.F7     Document Type: Article

References (73)

1. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001;32:181-184.
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
3. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
4. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-755.
5. Evans D, Beckett L, Field T, et al. Apolipoprotein E e4 and incidence of Alzheimer disease in a community population of older persons. JAMA 1997;277:822-824.
6. Breitner JC, Jarvik GP, Plassman BL, Saunders AM, Welsh KA. Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord 1998;12:40-44.
7. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology 1996;46:673-677.
8. Sparks DL, Scheff SW, Liu H, et al. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. J Neurol Sci 1996;138:97-104.
9. Ghebremedhin E, Schultz C, Thal DR. Gender and age modify the association between APOE and AD-related neuropathololgy. Neurology 2001;56:1696-1701.
10. Landen M, Thorsell A, Wallin A, Blennow K. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;61:352-356.
11. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335.
12. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17:525-530.
13. Pitas RE, Ji ZS, Weisgraber K.H, Mahley RW. Role of apolipoprotein E in modulating neurite outgrowth: potential effect of intracellular apolipoprotein E. Biochem Soc Trans 1998;26:257-262.
14. Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer's disease (CERAD): part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
15. Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology 1997;49:1580-1587.
16. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex beta amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999;158:469-490.
17. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001;49:202-213.
18. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205.
19. Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment and early Alzheimer's disease. Ann Neurol 2002;51:182-189.
20. McKhann G, Drachmann D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21. Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002;17:179-193.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the mental state of patients for the clinician. J Psychiatric Res 1975;12:189-198.
23. Welsh K, Butters N, Hughes JP, et al. Detection and staging of dementia in Alzheimer's disease: use of the neuropsychological measures developed for CERAD. Arch Neurol 1992;49:448-452.
24. Albert MS, Smith LA, Scherr PA, et al. Use of brief cognitive tests to identify individuals in the community with clinically-diagnosed Alzheimer's disease. Int J Neurosci 1991;57:167-178.
25. Wechsler D. Wechsler Memory Scale- revised manual. New York: Psychological Corporation, 1987.
26. Ekstrom RB, French JW, Harman HH, Dermen D. Manual for kit of factor-referenced cognitive tests. Princeton: Educational Testing Service, 1976.
27. Blair JR, Spreen O. Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin Neuropsychol 1989;3:129-136.
28. Goodglass H, Weintraub S. The Boston Naming Test. Philadelphia: Lea & Febiger, 1983.
29. Nelson HE. National Adult Reading Test (NART): test manual. Windsor, UK: NFER Nelson, 1982.
30. Cooper JA, Sagar HJ. Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources. J Clin Exp Neuropsychol 1993;15:713-731.
31. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-2122.
32. Craik F. A functional account of age differences in memory. In: Klix, Hagendorf H, eds. Human memory and cognitive capabilities: mechanisms and performances. Amsterdam: Elsevier Science Publishers BV, 1986:409-422.
33. Smith A. Symbol Digit Modalities Test manual-revised. Los Angeles: Western Psychological, 1984.
34. Benton AL, Sivan AB, Hamsher K, Varney NR, Spreen O. Contributions to neuropsychological assessment, 2nd ed. New York: Oxford University Press, 1994.
35. Raven JC, Court JH, Raven J. Standard progressive matrices. Raven manual, section 3. Oxford: Oxford Psychologists Press, 1992.
36. SAS Institute, Inc. SAS/STAT user's guide, version 8. Cary, NC: SAS Institute, 2000.
37. Wilson RS, Mendes de Leon CF, Barnes LL, et al. Participating in cognitively stimulating activities and risk of incident Alzheimer's disease. JAMA 2002;287:742-748.
38. Wilson RS, Beckett LA, Bennett DA, Albert M, Evans DA. Change in cognitive function among older persons from a community population: relation to age and Alzheimer's disease. Arch Neurol 1999;56:1274-1279.
39. Wilson RS, Gilley DW, Bennett DA, Hebert LE, Beckett LA, Evans DA. Person-specific paths of cognitive decline in Alzheimer's disease and their relation to age. Psychol Aging 2000;15:18-28.
40. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
41. Yamamoto Y, Hirano A. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 1986;12:3-9.
42. Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS. Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol Aging 1993;14:589-596.
43. Rosenthal R, Rosnow RL. Essentials of behavioral research: methods and data analysis, 2nd ed. New York: McGraw-Hill, 1991.
44. Mayeux R, Small SA, Tang M, Tycko B, Stern Y. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging 2001;22:683-689.
45. Wilson RS, Schneider JA, Barnes LL, et al. Effect of apolipoprotein E ε4 allele status on decline in different cognitive systems and development of Alzheimer's disease over a 6-year period. Arch Neurol 2002;59:1154-1160.
46. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
47. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
48. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
49. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999;402:533-537.
50. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-741.
51. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402:537-540.
52. Castano EM, Prelli F, Wisniewski T, et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J 1995;306:599-604.
53. Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994;372:92-94.
54. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA 2001;98:8838-8843.
55. Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. J Neurochem 1999;73:2613-2616.
56. Nathan BP, Jiang Y, Wong GK, Shen F, Brewer GJ, Stgruble RG. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res 2002;928:96-105.
57. Bales KR, Verina T, Cummins DJ, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999;96:15,233-15,238.
58. Carter DB, Dunn E, McKinley DD, et al. Human apolipoprotein E4 accelerates β-amyloid deposition in APPsw transgenic mouse brain. Ann Neurol 2001;50:468-475.
59. Holtzman DM, Fagan AM, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000;47:739-747.
60. Nagy ZA, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761.
61. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-1247.
62. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
63. McNamara MJ, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 1998;55:1001-1004.
64. Gearing M, Mori H, Mirra SS. Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996;39:395-399.
65. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
66. Crutcher KA, Clay MA, Scott SA, Tian X, Tolar M, Harmony JA. Neurite degeneration elicited by apolipoprotein E peptides. Exp Neurol 1994;130:120-126.
67. Fazekas F, Strasser-Fuchs S, Kollegger H, et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001;57:853-857.
68. Drory VE, Birnbaum M, Korczyn AD, Chapman J. Association of APOE varepsilon4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci 2001:190:17-20.
69. White F, Nicoll JA, Roses AD, Horsburgh K. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis 2001;8:611-625.
70. Horsburgh K, Graham DI, Stewart J, Nicoll JA. Influence of apolipoprotein E genotype on neuronal damage and ApoE immunoreactivity in human hippocampus following global ischemia. J Neuropathol Exp Neurol 1999;58:227-234.
71. Mauch DH, Nägler K, Schumacher S, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001;294:1354-1357.
72. Arendt T, Schindler C, Bruckner MK, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 1997;17:516-529.
73. Poirier J. Apolipoprotein E and Alzheimer's disease: a role in amyloid catabolism. Ann NY Acad Sci 2000;924:81-90.